News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
The average time of dilation lasts three to eight hours
More than 10,000 scientific publications containing EUDRAGIT
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Dozee Pro Ex will offer Ambulatory patient monitoring for a seamless continuum of patient monitoring across different care settings
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Subscribe To Our Newsletter & Stay Updated
